Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKB | Q96GD4 | 15/20 | 0.49 |
| ▸ | AURKA | O14965 | 14/20 | 0.49 |
| ▸ | PTK6 | Q13882 | 3/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | MARK3 | P27448 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12404633 | 0.90 | AURKB (0.51) | AURKBAURKAPTK6CHEK1LCK | |
| SCHEMBL12404644 | 0.89 | AURKB (0.51) | AURKBAURKAPTK6CHEK1LCK | |
| SCHEMBL12404640 | 0.88 | AURKB (0.49) | AURKBAURKAPTK6CHEK1LCK | |
| SCHEMBL14507639 | 0.84 | TTK (0.40) | AURKBAURKAPTK6 | |
| SCHEMBL14507430 | 0.84 | AURKA (0.59) | AURKBAURKAPTK6CHEK1LCK | |
| SCHEMBL14536779 | 0.83 | AURKB (0.44) | AURKBAURKAPTK6CHEK1LCK | |
| SCHEMBL12404632 | 0.80 | AURKB (0.51) | AURKBAURKAPTK6CHEK1LCK | |
| SCHEMBL12471674 | 0.80 | CHEK1 (0.66) | AURKBAURKAPTK6CHEK1LCK | |
| SCHEMBL14508090 | 0.79 | TTK (0.40) | AURKBAURKAPTK6 | |
| SCHEMBL8247338 | 0.78 | AURKA (0.73) | AURKBAURKACHEK1LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110183933-A1 | NOVEL MODULATORS OF CELL CYCLE CHECKPOINTS AND THEIR USE IN COMBINATION WITH CHECKPOINT KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2011-07-28 | — | — | US | disclosed |
| US-20110183933-A1 | NOVEL MODULATORS OF CELL CYCLE CHECKPOINTS AND THEIR USE IN COMBINATION WITH CHECKPOINT KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2011-07-28 | — | — | US | disclosed |
| WO-2007058942-A2 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2007-05-24 | — | — | WO | disclosed |
| US-20070117804-A1 | Imidazopyrazines as protein kinase inhibitors | SCHERING CORPORATION | 2007-05-24 | — | — | US | disclosed |
| US-20070117804-A1 | Imidazopyrazines as protein kinase inhibitors | SCHERING CORPORATION | 2007-05-24 | — | — | US | disclosed |
| WO-2007056468-A1 | METHODS FOR INHIBITING PROTEIN KINASES | SCHERING CORPORATION (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070105864-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-05-10 | — | — | US | disclosed |
| US-20070105864-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183933-A1 | NOVEL MODULATORS OF CELL CYCLE CHECKPOINTS AND THEIR USE IN COMBINATION WITH CHECKPOINT KINASE INHIBITORS | CDC25C, CHEK1, CDC25A | AURKB 27/4885AURKA 40/4885PTK6 639/4885 |
| US-20070117804-A1 | Imidazopyrazines as protein kinase inhibitors | CHEK1, CHEK2, CDKN1A | AURKB 138/4885AURKA 41/4885PTK6 292/4885 |
| US-20070105864-A1 | Methods for inhibiting protein kinases | PIM1, PIM2, PIM3 | AURKB 24/4885AURKA 5/4885PTK6 443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.